Medikaloka Hermina Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Medikaloka Hermina is forecast to grow earnings and revenue by 14.7% and 12.2% per annum respectively. EPS is expected to grow by 19.1% per annum. Return on equity is forecast to be 16.4% in 3 years.

Anahtar bilgiler

14.7%

Kazanç büyüme oranı

19.1%

EPS büyüme oranı

Healthcare kazanç büyümesi	18.8%
Gelir büyüme oranı	12.2%
Gelecekteki özkaynak getirisi	16.4%
Analist kapsamı	Good
Son güncelleme	02 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

IDX:HEAL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (IDR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	8,610,387	873,204	317,349	1,864,479	8
12/31/2025	7,561,508	709,883	200,664	1,574,925	11
12/31/2024	6,727,582	609,754	-24,000	1,344,350	10
9/30/2024	6,580,738	556,666	-974,007	1,311,996	N/A
6/30/2024	6,436,894	578,161	-705,967	1,381,139	N/A
3/31/2024	6,137,900	519,392	-475,821	1,391,603	N/A
12/31/2023	5,784,086	437,346	-271,707	1,319,655	N/A
9/30/2023	5,489,476	401,911	-122,712	1,167,233	N/A
6/30/2023	5,228,871	336,552	-51,646	1,079,147	N/A
3/31/2023	5,045,373	296,249	-26,339	1,044,610	N/A
12/31/2022	4,901,810	298,596	-261,272	867,738	N/A
9/30/2022	4,884,192	468,353	720,340	2,083,345	N/A
6/30/2022	5,135,152	615,705	617,067	1,892,838	N/A
3/31/2022	5,493,169	823,971	677,633	1,921,469	N/A
12/31/2021	5,869,014	995,974	642,792	1,856,336	N/A
9/30/2021	6,160,265	984,449	-450,591	585,680	N/A
6/30/2021	5,782,130	913,638	-155,479	930,786	N/A
3/31/2021	5,017,031	684,631	-237,869	776,409	N/A
12/31/2020	4,416,042	473,222	236,833	1,126,485	N/A
9/30/2020	3,826,030	307,234	485,466	1,233,835	N/A
6/30/2020	3,574,963	234,966	151,936	776,577	N/A
3/31/2020	3,713,290	270,753	242,020	846,451	N/A
12/31/2019	3,630,940	255,367	-3,362	572,580	N/A
9/30/2019	3,457,550	224,197	-345,366	266,934	N/A
6/30/2019	3,330,819	178,976	-345,148	249,389	N/A
3/31/2019	3,213,504	143,733	-328,973	281,638	N/A
12/31/2018	3,058,091	124,374	-522,491	241,671	N/A
9/30/2018	3,002,728	122,143	-449,194	372,664	N/A
6/30/2018	2,911,813	96,985	N/A	441,828	N/A
3/31/2018	2,783,426	99,344	N/A	408,610	N/A
12/31/2017	2,678,197	97,549	N/A	480,785	N/A
12/31/2016	2,234,263	61,996	N/A	362,845	N/A
12/31/2015	1,709,020	19,298	N/A	255,710	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: HEAL's forecast earnings growth (14.7% per year) is above the savings rate (6.8%).

Kazançlar ve Piyasa: HEAL's earnings (14.7% per year) are forecast to grow slower than the ID market (20.5% per year).

Yüksek Büyüme Kazançları: HEAL's earnings are forecast to grow, but not significantly.

Gelir ve Pazar: HEAL's revenue (12.2% per year) is forecast to grow faster than the ID market (10% per year).

Yüksek Büyüme Geliri: HEAL's revenue (12.2% per year) is forecast to grow slower than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: HEAL's Return on Equity is forecast to be low in 3 years time (16.4%).

Medikaloka Hermina Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 13%

Price target increased to Rp2,170

Consensus EPS estimates fall by 17%

Price target increased to Rp1,427

Consensus EPS estimates fall by 15%

Consensus forecasts updated

Recent updates

Third quarter 2024 earnings released: EPS: Rp8.39 (vs Rp10.11 in 3Q 2023)

Key Executive recently bought Rp109b worth of stock

President Director recently bought Rp5.0b worth of stock

Second quarter 2024 earnings released: EPS: Rp10.25 (vs Rp6.45 in 2Q 2023)

President Director recently bought Rp8.3b worth of stock

Consensus EPS estimates increase by 13%

Investor sentiment improves as stock rises 17%

Now 20% overvalued

First quarter 2024 earnings released: EPS: Rp12.96 (vs Rp7.52 in 1Q 2023)

Full year 2023 earnings released: EPS: Rp30.16 (vs Rp20.64 in FY 2022)

New minor risk - Shareholder dilution

President Director recently bought Rp308m worth of stock

Key Executive recently bought Rp687m worth of stock

Third quarter 2023 earnings released: EPS: Rp10.12 (vs Rp5.61 in 3Q 2022)

Key Executive recently bought Rp12b worth of stock

Second quarter 2023 earnings released: EPS: Rp6.45 (vs Rp3.68 in 2Q 2022)

Price target increased to Rp2,170

Less than half of directors are independent

Consensus EPS estimates fall by 17%

PT Medikaloka Hermina Tbk Ordinary Shares to Be Deleted from OTC Equity

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target increased to Rp1,427

Consensus EPS estimates fall by 15%

Less than half of directors are independent

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

PT Medikaloka Hermina Tbk (IDX:HEAL) announces an Equity Buyback for 80,000,000 shares, for IDR 116,000 million.

Third quarter 2021 earnings released: EPS Rp15.57 (vs Rp10.64 in 3Q 2020)

Price target increased to Rp1,255

Second quarter 2021 earnings released

Consensus EPS estimates increase to Rp50.58

Investor sentiment improved over the past week

Consensus EPS estimates increase to Rp222

Price target increased to Rp5,756

First quarter 2021 earnings released: EPS Rp95.79 (vs Rp24.16 in 1Q 2020)

Price target increased to Rp5,150

Consensus EPS estimates increase to Rp173

Price target increased to Rp4,959

Consensus EPS estimates increase to Rp160

New 90-day high: Rp4,200

New 90-day high: Rp4,000

New 90-day high: Rp3,930

Analysts update estimates

Price target raised to Rp4,368

New 90-day high: Rp3,450

Third quarter 2020 earnings released: EPS Rp53.13

First half earnings released

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin